While the present study establishes proof-of-concept with focus on the mechanisms for improved homing late in disease when AML-derived microenvironmental changes occur in the BM, future studies will have to address the therapeutic potential of this approach and how it for instance contributes to reduce tumor burden and improve survival when adoptive NK cell infusion is combined with for instance an AML-targeting BiKE or TriKE, chemotherapy prior cell therapy or when the NK cells are equipped with a CAR. This evidence concerns the gene BMP2K and neoplasm.